Últimas noticias sobre Oncolytics Biotech (NASDAQ:ONCY) Bolsa

Oncolytics Biotech

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

New,York,,Usa,-,January,07,,2025:,E2open,Website,Displayed

ABEO

BLMZ

CMBM

DGLY

DGNX

ETWO

GORV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IMNN

IXHL

ONCY

PMAX

PRTA

SBET

SILO

VVPR

WORX

Consulta las acciones con mayores subidas y caídas en el premercado estadounidense de hoy, incluyendo tecnológicas, biotecnológicas y más.

Las acciones de E2open se disparan un 25%; aquí están 20 acciones que se mueven en el premercado

Oncolytics Biotech Inc

WIIM

Oncolytics Biotech shares are trading higher after the company announced it appointed Jared Kelly as CEO.

Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors.
<img src="https://mma.prnewswire.com/media/2408622/5364608/Oncolytics_Biotech_Inc_Logo.jpg" alt="Oncolytics Biotech Inc Logo" />
Mr. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy. Most recently, he played a central role in orchestrating the sale of&nbsp;Ambrx Biopharma to Johnson &amp; Johnson for $2 billion. Prior to Ambrx, he advised multiple leading-edge biotech companies on M&amp;A and licensing transactions at highly respected law firms, including Lowenstein Sandler LLP and Kirkland &amp; Ellis LLP. He is a JD and LLM graduate of Georgetown Law.
"Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of Oncolytics' Board of Directors and outgoing Interim CEO. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors."
Mr. Kelly added, "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients. With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders."
Pelareorep, an intravenously-administered immunotherapeutic agent, has been granted FDA Fast Track designation by the U.S. Food and Drug Administration (FDA) in metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC). It has delivered compelling results in mPDAC, a high-value indication with significant unmet need. In Phase 1 and 2 trials involving more than 140 mPDAC patients, pelareorep has delivered a &gt;60% objective response rate in tumor evaluable patients in the most recent study, which is more than double the benefit observed in historical control trials, and, separately, two-year survival rates 4-6 times those observed in control patients or against the benchmark in prior studies.
In mBC, pelareorep recorded a meaningful survival benefit in two randomized Phase 2 studies of over 100 combined mBC patients, IND-213 and BRACELET-1. Phase 2 objective response rate data in second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA) patients continue to exceed historical data for treatment with a checkpoint inhibitor alone. These consistent efficacy signals, in combination with multiple chemotherapies and checkpoint inhibitors, uniquely position pelareorep as a high-potential asset for further development in-house and/or through strategic partnerships. Pelareorep also has a well-defined and favorable safety profile based on data from &gt;1,100 patients across multiple tumor types.
As a material inducement to Mr. Kelly's appointment as Chief Executive Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Kelly has been awarded an initial stock option grant exercisable for 2,850,000 shares with an exercise price of CAD$0.57, vesting equally over three years. He also received a performance-based stock option grant exercisable for 1,900,000 shares with an exercise price of CAD$0.57, which will vest upon the achievement of certain financing objectives. All stock option grants have a term of 5 years from the date of grant. The Company also granted Mr. Kelly restricted stock units, which will entitle him to receive that number of Common Shares equal to 2% of the Company's then outstanding common shares upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep. Each of these awards is intended to align Mr. Kelly's long-term incentives with the creation of shareholder value.

News

Management

TSX:ONC

Oncolytics Names Jared Kelly CEO, Wayne Pisano Steps Down After Guiding Immunotherapy Progress

Shares of E2open Parent Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) rose sharply in today's pre-market trading after the company agreed to be acquired by WiseTech Global for $3.30 per share in all-cash deal <a href="https://www.benzinga.com/quote/ETWO">following strategic review</a>.
E2open Parent shares jumped 25.2% to $3.22 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>SCWorx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) rose 52.5% to $0.6138 in pre-market trading.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) jumped 37.5% to $7.43 in pre-market trading after falling 8% on Friday.</li>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) surged 28.7% to $0.2799 in pre-market trading after gaining 8% on Friday. Incannex Healthcare, last week, announced it filed a prospectus supplement to increase the shares offered under its sales agreement to be worth $2.51 million.</li>
<li>CNFinance Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) surged 20% to $0.57 in pre-market trading after dipping 12% on Friday. CNFinance will hold Annual General Meeting on May 29.</li>
<li>Diginex Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares jumped 18% to $ 67.23 in pre-market trading after the company announced the signing of a Memorandum of Understanding for an all-share acquisition of Matter DK ApS.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) climbed 16.7% to $2.92 in pre-market trading. Digital Ally, last week, announced a 1-for-100 reverse stock split.</li>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) gained 16.2% to $0.4984 in pre-market trading.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) rose 14.7% to $7.72 in pre-market trading after gaining 79% on Friday.</li>
<li>VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) gained 14.1% to $6.99 in pre-market trading after gaining 24% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 31.6% to $4.50 in pre-market trading after the company disclosed that Phase 3 AFFIRM-AL clinical trial for Birtamimab in patients with AL Amyloidosis did not meet primary endpoint.</li>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) fell 29.7% to $0.8151 in pre-market trading after the company reported up to $9.75 million private placement priced at-the-market under Nasdaq rules.</li>
<li>Oncolytics Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) shares dipped 25.9% to $0.31 in pre-market trading after gaining 4% on Friday.</li>
<li>Powell Max Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) fell 17.2% to $0.4221 in pre-market trading after jumping 57% on Friday.</li>
<li>Lazydays Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) shares tumbled 16.7% to $0.24 in pre-market trading after surging 55% on Friday.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) dipped 14.6% to $0.1790 in pre-market trading after jumping more than 56% on Friday. BloomZ, last week, announced a business alliance with M-NEXT holdings.</li>
<li>Cambium Networks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) fell 11.7% to $0.37 in today's pre-market trading after dipping more than 10% on Friday.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) declined 9.8% to $14.29 in pre-market trading after gaining more than 4% on Friday.</li>
<li>EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) shares fell 8.9% to $15.45 in pre-market trading. EHang Holdings posted a first-quarter adjusted loss of 6 cents per share, versus a year-ago loss of 2 cents per share.</li>
<li>Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) fell 6.1% to $6.03 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses
New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors
Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer
SAN DIEGO and CALGARY, AB, May 23, 2025 /PRNewswire/ -- Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment.

Oncolytics Biotech To Present New Data From Phase I/II GOBLET Clinical Trial At 2025 ASCO Annual Meeting

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) with a Buy and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target

Jones Trading analyst Soumit Roy downgrades Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) from Buy to Hold.

Downgrades

Jones Trading Downgrades Oncolytics Biotech to Hold

Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year.

Earnings

Earnings Beats

Oncolytics Biotech Q1 EPS $(0.06) Beats $(0.09) Estimate

ADCT

AEVA

AFCG

ALUR

ARCO

ATER

AYTU

BCDA

BITF

BNGO

The Beachbody Company, Inc. Class A Common Stock

BODI

BOOT

BRTX

BZAI

CAAS

CANG

CCAP

CDXS

CELC

CLBT

CLSD

CREX

CSCO

CSPI

CSWC

CTSO

DAVA

DERM

DRIO

DYAI

EGAN

ELVA

EPSN

EWCZ

FIHL

FOSL

GCTS

GLBE

GROV

GWRS

HWKN

IBTA

ICCC

INVZ

IREN

ISSC

ITRG

JACK

KARO

KITT

KMDA

KRNT

LAZR

LDTC

LIEN

LIQT

LOCL

LUCD

LUXE

LVLU

MDXH

MGRM

MMYT

NEXN

NSYS

NTWK

NVGS

NYXH

PDSB

PYPD

RCAT

RDCM

REKR

RELI

RSKD

SBLK

SCPH

SDHC

SDOT

SDST

SGML

SHIM

Earnings Scheduled For May 14, 2025

Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-14. Here's what investors need to know before the announcement.
Analysts estimate that Oncolytics Biotech will report an earnings per share (EPS) of $-0.09. 
Investors in Oncolytics Biotech are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Oncolytics Biotech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.07</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.09</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-8.0%</td>
<td>-1.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747162975_0.png" alt="eps graph" />
<h3>Performance of Oncolytics Biotech Shares</h3>
Shares of Oncolytics Biotech were trading at $0.5385 as of May 12. Over the last 52-week period, shares are down 55.55%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ONCY/earnings">To track all earnings releases for Oncolytics Biotech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Oncolytics Biotech's Upcoming Earnings Report

ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients
Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers
&nbsp;Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, will present&nbsp;new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options.
"Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. "In multiple studies, pelareorep has repeatedly demonstrated its ability to engage the immune system to attack pancreatic cancer tumors, which has the potential to improve outcomes for patients battling this difficult-to-treat cancer."

Biotech

General

Oncolytics Biotech Annunces It Will Present New Data From Cohort 1 Of The Goblet Study At 2025 American Society Of Clinical Oncology Annual Meeting In Chicago May 30-June 3, 2025

Oncolytics Biotech shares are trading higher after the company secured up to $20 million in flexible funding for the development of Pelareorep through a share purchase agreement with Alumin Capital.

Reported Earlier, Oncolytics Biotech Secures Up To $20M In Flexible Funding For Pelareorep Development Through Share Purchase Agreement With Alumni Capital

RBC Capital analyst Douglas Miehm maintains Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) with a Outperform and lowers the price target from $6 to $5.

RBC Capital Maintains Outperform on Oncolytics Biotech, Lowers Price Target to $5

Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.42) by 2.38 percent. This is unchanged from the same period last year.

Oncolytics Biotech FY 2024 GAAP EPS C$(0.41) Beats C$(0.42) Estimate, Cash Position Of $15.9M Provides Runway Into Third Quarter 2025

<h3>Companies Reporting Before The Bell</h3>
• Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report quarterly loss at $6.50 per share on revenue of $16.62 million. 
• Lifeward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $7.30 million. 
• Mammoth Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $46.70 million. 
• BeOne Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) is projected to report earnings for its fourth quarter. 
• Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) is estimated to report earnings for its fourth quarter. 
• Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $863.39 million. 
• inTest (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INTT#AMEX">INTT</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $35.25 million. 
• Genesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>) is projected to report quarterly earnings at $3.23 per share on revenue of $736.11 million. 
• YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $3.97 billion. 
• Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $432.38 million. 
• WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $22.53 million. 
• Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $642.37 million. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMCT

INTT

LFWD

TUSK

Earnings Scheduled For March 7, 2025

Oncolytics Biotech Continues To Make Good Progress In 2025 With Key Regulatory And Clinical Advancements, Reinforcing Pelareorep's Potential In Hard-to-treat Cancers

Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on February 13, 2025 indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company's ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice provides that the Company has a period of 180 calendar days from the date of the Notice, or until August 12, 2025, to regain compliance with the minimum bid price requirement.

Oncolytics Biotech Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Reported Friday, Oncolytics Biotech CEO And Co-Founder Matt Coffey To Step Down; Wayne Pisano To Continue As Interim CEO During Successor Search

Events

Oncolytics Biotech To Present At 2025 ASCO GI Symposium Jan. 23-25

Small Cap

Opinion

Press Releases

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

After Major Oncology Conference, All Eyes Turn to Industry Innovation

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

ACLX

AKYA

ANIX

ARVN

BCTX

BNTX

CATX

CGON

CTOR

CTXR

GALT

IBRX

IOVA

PRPH

QTRX

REGN

STRO

TCRX

TPST

TSX:BCT

HC Wainwright & Co.

Maxim Group

RBC Capital

Raymond James

Canaccord Genuity

Screenshot 2024-08-13 at 5.40.41 PM

Extending Survival: Oncolytics Biotech&#39;s Pelareorep Shows Promise In Fighting Metastatic Breast Cancer

Screenshot 2024-07-29 at 6.05.52 PM

Pancreatic Cancer Could Overtake Colorectal Cancer To Become Second Leading Cause Of Cancer Death – Oncolytics Is Working On A Promising Treatment

Screenshot 2024-03-06 at 6.25.21 PM

Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC) Fights Cancer With Pelareorep, Which Has Received FDA Fast Track Designation For Breast And Pancreatic Cancer

Comments

Oncolytics Biotech

Noticias

Últimas noticias sobre Oncolytics Biotech (NASDAQ:ONCY) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL